Xsulin 30/70 Suspension for Injection contains human insulin at a concentration of 100 IU/mL and is formulated as an intermediate-acting insulin suspension comprising 30% soluble insulin and 70% isophane insulin. It is indicated for the management of diabetes mellitus in adults and children requiring insulin therapy to achieve optimal glycemic control. The soluble fraction provides an initial rapid onset of action, while the isophane component ensures a prolonged duration, facilitating basal insulin coverage. Xsulin 30/70 is administered via subcutaneous injection, with dosage individualized based on patient-specific factors including blood glucose monitoring results, dietary intake, and physical activity. It is essential to rotate injection sites to minimize lipodystrophy. This insulin suspension should not be administered intravenously or intramuscularly. Patients must be educated on recognizing and managing hypoglycemia, a potential adverse effect associated with insulin therapy. Proper storage at 2–8°C is required to maintain potency, avoiding freezing or exposure to direct heat or light. Xsulin 30/70 may be used alone or in combination with other antidiabetic agents under medical supervision. Regular monitoring of blood glucose and periodic assessment of HbA1c levels are recommended to optimize therapeutic outcomes and reduce the risk of diabetes-related complications.